PCRX vs SYK
PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain. SYK: A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve over 150 million patients annually across 61 countries.
Side-by-side fundamentals
| Metric | PCRX | SYK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $25.59 | $309.24 | |
| Market cap as of 2026-07-23 | $1.0B | $119.6B | |
| P/E as of 2026-07-23 | 194.68 | 35.83 | SYK lower |
| PEG as of 2026-07-23 | 17.75 | 3.29 | SYK lower |
| Net margin as of 2026-07-23 | +0.7% | +13.2% | SYK higher |
| Gross margin as of 2026-07-23 | +79.3% | +64.2% | PCRX higher |
| Operating margin as of 2026-07-23 | +0.1% | +19.7% | SYK higher |
| ROE as of 2026-07-23 | +0.7% | +15.1% | SYK higher |
| ROA as of 2026-07-23 | +0.4% | +7.1% | SYK higher |
| Debt / equity as of 2026-07-23 | 0.56 | 0.64 | PCRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +4.6% | +8.8% | SYK higher |
| Revenue CAGR (3y) SEC XBRL | +2.9% | +10.8% | SYK higher |
| Dividend yield as of 2026-07-23 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.26 | 0.78 | |
| 1-year return as of 2026-07-22 close | +14.1% | -21.7% | PCRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.